# Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

> **NCT00705549** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 88 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Vinorelbine
- **DRUG:** Pemetrexate

## Key facts

- **NCT ID:** NCT00705549
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2013-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705549, "Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT00705549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*